Lung Diseases, Interstitial Clinical Trial
Official title:
Popcorn Lung: the Discovery of a New Disease
NCT number | NCT00027235 |
Other study ID # | NCRR-M01RR00036-0829 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | November 28, 2001 |
Last updated | June 23, 2005 |
Recently, an epidemic of pulmonary disease has been recognized among workers in a popcorn factory in Jasper, Missouri. The exposure agent has not yet been identified, but suspects include butter flavoring and the powdered salt used in the mixing room. This disease resembles "Bronchiolitis Obliterans Syndrome", an illness that makes it difficult to breathe. Of the 117 workers studied, one year later, 25 subjects whom were working in the mixing room or in the microwave packaging area have had decreases in lung function seven times the norm for their age. Industrial hygiene experts revealed that dust concentrations of salt and other flavorings were much higher in the mixing room compared to the office and outdoor work areas. Recently, rats were exposed to vapors created by heating the butter flavor compound obtained from this plant. Six-hour exposure to vapors at very high concentration resulted in significant damage to the breathing apparatus. Thus, there is clinical, epidemiological, and animal toxicity data that appears to implicate some constituent present during the mixing of the butter flavoring, salt, and oil causing a form of obstructive airway disease that has been rapidly progressive in a number of workers. It is not clear what the pathophysiologic nature of this entity is, though it resembles Bronchiolitis Obliterans Syndrome. It is not known what the long term consequence of this will be on the active workers, nor is it clear whether preventive measures taken to reduce exposures in the mixing room and elsewhere in the plant are going to be effective.
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility | Current employees who have a decline in FEV1 larger than 200cc within the past year will be eligible to participate. All index cases will be eligible to participate. |
Observational Model: Defined Population, Time Perspective: Longitudinal
Country | Name | City | State |
---|---|---|---|
United States | Washington University, Division of Pulmonary and Critical Care Medicine | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
National Center for Research Resources (NCRR) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04119115 -
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
|
||
Active, not recruiting |
NCT04559581 -
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
|
||
Recruiting |
NCT05151640 -
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
|
||
Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT02251964 -
Rituximab in Interstitial Pneumonitis
|
Phase 2/Phase 3 | |
Terminated |
NCT01432080 -
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
|
Phase 2 | |
Completed |
NCT01442779 -
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT05866198 -
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
|
N/A | |
Active, not recruiting |
NCT05321082 -
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
|
Phase 3 | |
Completed |
NCT04016168 -
Idiopathic Pulmonary Fibrosis and Serum Bank
|
||
Recruiting |
NCT00258583 -
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
|
||
Recruiting |
NCT05855109 -
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
|
||
Completed |
NCT05719233 -
Assessment of Neuropsychiatric Function in Patients With Interstitial Lung Disease
|
||
Recruiting |
NCT04159129 -
Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
|
||
Completed |
NCT03313180 -
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
|
Phase 3 | |
Completed |
NCT05065190 -
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
|
Phase 3 | |
Completed |
NCT03136120 -
Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
|
||
Recruiting |
NCT04930666 -
BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease
|
||
Recruiting |
NCT05503030 -
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
|